Kaskas Nadine, Merola Joseph F, Qureshi Abrar A, Paek So Yeon
From the Department of Dermatology, Warren Alpert Medical School, Brown University, Providence, Rhode Island; Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
N. Kaskas, MD, Department of Dermatology, Warren Alpert Medical School, Brown University; J.F. Merola, MD, MMSc, Brigham and Women's Hospital, Harvard Medical School; A.A. Qureshi, MD, MPH, Department of Dermatology, Warren Alpert Medical School, Brown University; S.Y. Paek, MD, FAAD, Warren Alpert Medical School, Brown University.
J Rheumatol. 2017 May;44(5):695-696. doi: 10.3899/jrheum.170149.
Recent groundbreaking therapies for psoriasis target specific pathways that drive this systemic inflammatory disease. However, patients with nonplaque psoriasis phenotypes often do not qualify for these therapies and are currently undertreated because of the criteria used during the development of novel agents. We propose use of the phrase "polyphenotypic psoriasis" to describe both plaque and nonplaque subtypes, as well as single and multiple phenotype involvement in individual patients. The goal of using the phrase "polyphenotypic psoriasis" is to remind clinicians about the heterogeneous manifestations of psoriasis in addition to chronic plaque psoriasis.
近期针对银屑病的突破性疗法靶向驱动这种全身性炎症性疾病的特定通路。然而，非斑块型银屑病表型的患者通常不符合这些疗法的适用条件，并且由于新型药物研发过程中所采用的标准，他们目前未得到充分治疗。我们建议使用“多表型银屑病”这一术语来描述斑块型和非斑块型亚型，以及个体患者中单一和多种表型的累及情况。使用“多表型银屑病”这一术语的目的是除了提醒临床医生注意慢性斑块型银屑病外，还要注意银屑病的异质性表现。
